Sirolimus in the treatment of vascular anomalies

Abstract

Despite that the large, diversified group known as vascular anomaly represents vascular tumors and vascular malformations together, the authors successfully clarified different outcomes of sirolimus with these two entirely different groups of vascular disorders.1 Indeed, vascular tumors/hemangioma are the outcome of increased neoplastic endothelial cell proliferation, but vascular malformations are the outcome of the defective development of any part of the circulation system during embryogenesis.